News

Icario Names Bryan Perler Chief Financial and Administrative Officer

Former Zelis and Sapphire Digital Executive Brings a Proven Track Record of Driving Growth and Profitability at ScaleMINNEAPOLIS, Aug. 23,…

2 years ago

Acer Therapeutics to Participate in August and September 2022 Investor Conferences

NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition,…

2 years ago

Marijuana Strategic Ventures, Inc. (OTC: MSVI) Now Mushrooms Inc., Announces Filing of Provisional Patent for Novel Mycelium Thread

Mycothread Manufacturing Patent Exclusively Licensed to CompanyESTERO, Fla., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Marijuana Strategic Ventures, Inc. (the “Company”)(OTC:…

2 years ago

Nanomix Enters into Distribution Agreement for the eLab System and Future New Products with BIOASIA PTE LTD in Singapore

SAN LEANDRO, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in…

2 years ago

WIMI Hologram Academy: The Application of 3D modeling Technology in Digital Anatomical Models

HONG KONG, Aug. 23, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,…

2 years ago

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy

Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure SION™ Surgical Instrument by Sight Sciences, Inc.…

2 years ago

SI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference

SANTA CLARA, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving…

2 years ago

Recce Pharmaceuticals Announces Positive Safety Data from Seventh Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Highlights: 10 subjects in cohort seven were intravenously dosed with RECCE® 327 at 6,000mg Independent Safety Committee reviewing cohort seven…

2 years ago

Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers

Initial focus of five-year collaboration will be on potentially best-in-class ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, which together comprise…

2 years ago